Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5041 in Metastatic Castration-resistant Prostate Cancer
NCT05942001Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Aug 2023
- Primary completion
- Sep 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS-5041 in prostate cancer (PCa) (4 arms), sponsored by Hengrui. Primary endpoints: Dose-limiting toxicity at 28 days, Maximum tolerated dose at 28 days and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
HRS-5041
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05942001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942001.